StockData
Johnson & Johnson logo

Johnson & Johnson (JNJ) operating KPIs

JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value
$273.20−2.00 (-0.73%)

Close on Oct 30, 2026Market cap $658.38BP/E 31.7Yield 1.88%

Johnson & Johnson other Oncology medicines — Worldwide operational (constant-currency) growth YoY (%) (%)

Form 8-K EX-99.2 Segment Sales Schedule

QuarterlyAnnual
Latest, Q3 2026
26.7%
Period ended Sep 30, 2026
Change on a year earlier
+19.0 pts
7.7% in Q3 2025
History
32 quarters
Since Q4 2017
Sources
32
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedOther Oncology medicines — Worldwide operational (constant-currency) growth YoY (%) (%)Year on yearSource
Q3 2026Sep 30, 202626.7%+19.0 ptsForm 8-K (a2026q3exhibit991.htm, filed 2026-10-13) ↗
Q2 2026Jun 28, 2026-3.9%-13.6 ptsForm 8-K (a2026q2exhibit991.htm, filed 2026-07-15) ↗
Q1 2026Mar 29, 2026-12.5%-37.2 ptsForm 8-K (a2026q1exhibit991.htm, filed 2026-04-14) ↗
Q4 2025Dec 28, 202530.3%-62.1 ptsForm 8-K (a2025q4exhibit991.htm, filed 2026-01-21) ↗
Q3 2025Sep 28, 20257.7%–Form 8-K (a2025q3exhibit991.htm, filed 2025-10-14) ↗
Q2 2025Jun 29, 20259.7%-77.5 ptsForm 8-K (a2025q2exhibit991.htm, filed 2025-07-16) ↗
Q1 2025Mar 30, 202524.7%-55.8 ptsForm 8-K (a2025q1exhibit991.htm, filed 2025-04-15) ↗
Q4 2024Dec 29, 202492.4%–Form 8-K (a2024q4exhibit991.htm, filed 2025-01-22) ↗
Q2 2024Jun 30, 202487.2%–Form 8-K (a2024q2exhibit991.htm, filed 2024-07-17) ↗
Q1 2024Mar 31, 202480.5%+39.5 ptsForm 8-K (a2024q1exhibit991.htm, filed 2024-04-16) ↗
Q1 2023Apr 2, 202341.0%+73.3 ptsForm 8-K (a2023q1exhibit991.htm, filed 2023-04-18) ↗
Q4 2022Jan 1, 202326.7%+55.5 ptsForm 8-K (a2022q4exhibit991.htm, filed 2023-01-24) ↗
Q3 2022Oct 2, 202230.2%+67.1 ptsForm 8-K (a2022q3exhibit991.htm, filed 2022-10-18) ↗
Q2 2022Jul 3, 202214.4%+57.4 ptsForm 8-K (a2022q2exhibit991.htm, filed 2022-07-19) ↗
Q1 2022Apr 3, 2022-32.3%-14.4 ptsForm 8-K (a2022q1exhibit991.htm, filed 2022-04-19) ↗
Q4 2021Jan 2, 2022-28.8%-27.6 ptsForm 8-K (a2021q4exhibit991.htm, filed 2022-01-25) ↗

Breakdown

What makes up other oncology medicines — worldwide operational (constant-currency) growth yoy (%)

Cite this data

StockData. (2026). Johnson & Johnson Other Oncology medicines — Worldwide operational (constant-currency) growth YoY (%) (%), quarterly Q4 2017–Q3 2026 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug_other_onc_ops_yoy

See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.